These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 32854232

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
    Nasser Y, Labetoulle R, Harzallah I, Berger AE, Roblin X, Paul S.
    Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
    [Abstract] [Full Text] [Related]

  • 3. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
    Curci D, Lucafò M, Cifù A, Bramuzzo M, Martelossi S, Favretto D, De Pellegrin F, Fabris M, Vascotto F, Naviglio S, Ventura A, Stocco G, Decorti G.
    J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):474-479. PubMed ID: 31149938
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.
    Kato M, Sugimoto K, Ikeya K, Takano R, Matsuura A, Miyazu T, Ishida N, Tamura S, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Hanai H.
    PLoS One; 2021 Oct; 16(7):e0254548. PubMed ID: 34242369
    [Abstract] [Full Text] [Related]

  • 5. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.
    Gonczi L, Kurti Z, Rutka M, Vegh Z, Farkas K, Lovasz BD, Golovics PA, Gecse KB, Szalay B, Molnar T, Lakatos PL.
    BMC Gastroenterol; 2017 Aug 08; 17(1):97. PubMed ID: 28789636
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA.
    Valdés-Delgado T, Aguado-Paredes A, Merino-Bohórquez V, Martín-Manzanares J, Alonso MM, Maldonado B, Castro L, Belvis M, Benítez B, Caunedo Á, Calleja MÁ, Argüelles-Arias F.
    Dig Dis Sci; 2024 Jan 08; 69(1):228-234. PubMed ID: 37943382
    [Abstract] [Full Text] [Related]

  • 9. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
    Bodini G, Giannini EG, Savarino V, Del Nero L, Pellegatta G, De Maria C, Baldissarro I, Savarino E.
    Scand J Gastroenterol; 2016 Sep 08; 51(9):1081-6. PubMed ID: 27207330
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Therapeutic Drug Monitoring of Anti-TNFα Inhibitors: A Matter of Cut-Off Ranges.
    Cheli S, Savino D, Penagini F, Zuccotti G, Zuin G, Clementi E, Cattaneo D.
    Pharmaceutics; 2023 Jun 27; 15(7):. PubMed ID: 37514022
    [Abstract] [Full Text] [Related]

  • 13. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML, Karim S, Helms ETJ, Keating PE, Hock B, Stamp LK, Schultz M.
    Intern Med J; 2019 Apr 27; 49(4):513-518. PubMed ID: 30091273
    [Abstract] [Full Text] [Related]

  • 14. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
    Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S.
    Am J Gastroenterol; 2014 Aug 27; 109(8):1250-6. PubMed ID: 24913041
    [Abstract] [Full Text] [Related]

  • 15. Comparing Point-of-Care Technology to ELISA Testing for Infliximab and Adalimumab Levels in Adult Inflammatory Bowel Disease Patients: A Prospective Pilot Study.
    Bonazzi E, Maniero D, Lorenzon G, Bertin L, Bray K, Bahur B, Barberio B, Zingone F, Savarino EV.
    Diagnostics (Basel); 2024 Sep 26; 14(19):. PubMed ID: 39410544
    [Abstract] [Full Text] [Related]

  • 16. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
    Assa A, Matar M, Turner D, Broide E, Weiss B, Ledder O, Guz-Mark A, Rinawi F, Cohen S, Topf-Olivestone C, Shaoul R, Yerushalmi B, Shamir R.
    Gastroenterology; 2019 Oct 26; 157(4):985-996.e2. PubMed ID: 31194979
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M, Barreiro-de Acosta M, Echarri A, Almendros R, Barrio J, Llao J, Gomollón F, Vera M, Cabriada JL, Guardiola J, Guerra I, Beltrán B, Roncero O, Busquets D, Taxonera C, Calvet X, Ferreiro-Iglesias R, Ollero Pena V, Bernardo D, Donday MG, Garre A, Godino A, Díaz A, Gisbert JP.
    Dig Dis Sci; 2019 Mar 26; 64(3):846-854. PubMed ID: 30426297
    [Abstract] [Full Text] [Related]

  • 19. Relationship between Serum Adalimumab Levels and Clinical Outcome in the Treatment of Inflammatory Bowel Disease.
    Hinojosa J, Muñoz F, Martínez-Romero GJ.
    Dig Dis; 2019 Mar 26; 37(6):444-450. PubMed ID: 31039560
    [Abstract] [Full Text] [Related]

  • 20. Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients.
    Facchin S, Buda A, Cardin R, Agbariah N, Zingone F, De Bona M, Zaetta D, Bertani L, Ghisa M, Barberio B, Savarino EV.
    Therap Adv Gastroenterol; 2021 Mar 26; 14():1756284821999902. PubMed ID: 33815569
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.